Avecourt
ATX code: D07AC13 (Mometasone) Active substance: mometasone (mometasone) Rec.INN registered by WHO Dosage form AVECORT ointment for external use. approx. 0.1%: tube 15 or 30 g reg. No.: LP-001041 dated 10/21/11 - Active Release form, composition and packaging Ointment for external use 0.1% 1 g mometasone furoate 1 mg
15 g - aluminum tubes (1) - cardboard packs. 30 g - aluminum tubes (1) - cardboard packs.
Clinical-pharmacological group: GCS for external use Pharmaco-therapeutic group: Glucocorticosteroid for topical use
Pharmacological action: GCS for local use. Has anti-inflammatory and anti-allergic effects. Inhibits the release of inflammatory mediators. Increases the production of lipocortin, which is an inhibitor of phospholipase A2, which causes a decrease in the formation of arachidonic acid. Prevents the marginal accumulation of neutrophils, which reduces inflammatory exudate and cytokine production, inhibits the migration of macrophages, and leads to a decrease in the processes of infiltration and granulation. Reduces inflammation by reducing the formation of a chemotaxis substance (impact on “late” allergy reactions), inhibits the development of an “immediate” allergic reaction (due to inhibition of the production of arachidonic acid metabolites and a decrease in the release of inflammatory mediators from mast cells). Absorption of mometasone from 0.1% ointment through normal skin is 0.4% of the dose 8 hours after application without a bandage. When the skin is inflamed or damaged, absorption accelerates.
Side effects: Local reactions: burning, itching, paresthesia, folliculitis, acne, skin atrophy, hypertrichosis, hypopigmentation, perioral dermatitis, allergic contact dermatitis, skin maceration, secondary infection, striae, prickly heat. The likelihood of these adverse events occurring increases with the use of occlusive dressings.
Indications for use: Inflammation and itching of the skin in dermatoses (including psoriasis, atopic dermatitis), for which GCS therapy is indicated.
Contraindications: Hypersensitivity to any component of the drug or to other corticosteroids, rosacea, perioral dermatitis, bacterial, viral (Herpes simplex. Herpes zoster) or fungal skin infection, tuberculosis, syphilis, post-vaccination reactions, pregnancy (treatment of large areas of skin, long-term treatment), lactation period (use in large doses and/or for a long time), children under 2 years of age. With caution: application to the facial skin and intertriginous skin surface, use of occlusive dressings, as well as treatment of large areas of skin and/or long-term treatment (especially in children). The safety of mometasone during pregnancy and lactation has not been studied. GCS penetrate the placental barrier. Long-term treatment and the use of large doses during pregnancy should be avoided due to the risk of negative effects on fetal development. GCS are excreted in breast milk, so if GCS are to be used in large doses and/or for a long time, breastfeeding should be stopped.
Directions for use and dosage: Externally. A thin layer of ointment is applied to the affected areas of the skin once a day. Duration of treatment: 7-28 days, determined by the effectiveness of therapy, as well as the patient’s tolerability of the drug, the presence and severity of side effects.
Overdose: Symptoms: inhibition of the function of the hypothalamic-pituitary-adrenal system (including secondary adrenal insufficiency). Treatment is symptomatic. If necessary, correct electrolyte imbalance, discontinue the drug (for long-term therapy, gradual withdrawal).
Interaction: Interactions with other drugs have not been described to date. Due to the chemical properties of mometasone furoate, it is incompatible with alkalis.
Special instructions: If there is no effect within 2 weeks of drug therapy, the diagnosis should be clarified. When applied to large areas of skin for a long time, especially when using occlusive dressings, systemic action of GCS may develop. Given this, it is necessary to monitor the function of the hypothalamic-pituitary-adrenal system. Propylene glycol, which is part of the drug, may cause irritation at the site of application. In such cases, use of the drug should be discontinued and appropriate treatment should be prescribed. It should be borne in mind that GCS can change the manifestation of some skin diseases, which can complicate the diagnosis. In addition, the use of GCS may cause a delay in wound healing. With long-term therapy with GCS, sudden cessation of therapy can lead to the development of rebound syndrome, manifested in the form of dermatitis with intense redness of the skin and a burning sensation. Therefore, after a long course of treatment, the drug should be discontinued gradually, for example, by switching to an intermittent treatment regimen before stopping it completely. Due to the fact that in children the ratio of surface area to body weight is greater than in adults, children are at greater risk of suppressing the function of the hypothalamic-pituitary-adrenal system and developing Cushing's syndrome when using any topical corticosteroids. Long-term treatment of children with GCS can lead to disruption of their growth and development. The use of the drug in children for more than 3 weeks has not been studied. Children should receive the minimum dose of the drug sufficient to achieve an effect. There is no data on the adverse effects of the drug on the ability to drive vehicles and operate machinery.
Storage conditions: In a dry place at a temperature from +2C to +30C. Keep out of the reach of children.
Dispensing order: Dispensed by prescription
Avecort ointment external 0.1% 15 g tube/pack of cards x1
ATX code: D07AC13 (Mometasone) Active substance: mometasone (mometasone) Rec.INN registered by WHO Dosage form AVECORT ointment for external use. approx. 0.1%: tube 15 or 30 g reg. No.: LP-001041 dated 10/21/11 - Active Release form, composition and packaging Ointment for external use 0.1% 1 g mometasone furoate 1 mg
15 g - aluminum tubes (1) - cardboard packs. 30 g - aluminum tubes (1) - cardboard packs.
Clinical-pharmacological group: GCS for external use Pharmaco-therapeutic group: Glucocorticosteroid for topical use
Pharmacological action: GCS for local use. Has anti-inflammatory and anti-allergic effects. Inhibits the release of inflammatory mediators. Increases the production of lipocortin, which is an inhibitor of phospholipase A2, which causes a decrease in the formation of arachidonic acid. Prevents the marginal accumulation of neutrophils, which reduces inflammatory exudate and cytokine production, inhibits the migration of macrophages, and leads to a decrease in the processes of infiltration and granulation. Reduces inflammation by reducing the formation of a chemotaxis substance (impact on “late” allergy reactions), inhibits the development of an “immediate” allergic reaction (due to inhibition of the production of arachidonic acid metabolites and a decrease in the release of inflammatory mediators from mast cells). Absorption of mometasone from 0.1% ointment through normal skin is 0.4% of the dose 8 hours after application without a bandage. When the skin is inflamed or damaged, absorption accelerates.
Side effects: Local reactions: burning, itching, paresthesia, folliculitis, acne, skin atrophy, hypertrichosis, hypopigmentation, perioral dermatitis, allergic contact dermatitis, skin maceration, secondary infection, striae, prickly heat. The likelihood of these adverse events occurring increases with the use of occlusive dressings.
Indications for use: Inflammation and itching of the skin in dermatoses (including psoriasis, atopic dermatitis), for which GCS therapy is indicated.
Contraindications: Hypersensitivity to any component of the drug or to other corticosteroids, rosacea, perioral dermatitis, bacterial, viral (Herpes simplex. Herpes zoster) or fungal skin infection, tuberculosis, syphilis, post-vaccination reactions, pregnancy (treatment of large areas of skin, long-term treatment), lactation period (use in large doses and/or for a long time), children under 2 years of age. With caution: application to the facial skin and intertriginous skin surface, use of occlusive dressings, as well as treatment of large areas of skin and/or long-term treatment (especially in children). The safety of mometasone during pregnancy and lactation has not been studied. GCS penetrate the placental barrier. Long-term treatment and the use of large doses during pregnancy should be avoided due to the risk of negative effects on fetal development. GCS are excreted in breast milk, so if GCS are to be used in large doses and/or for a long time, breastfeeding should be stopped.
Directions for use and dosage: Externally. A thin layer of ointment is applied to the affected areas of the skin once a day. Duration of treatment: 7-28 days, determined by the effectiveness of therapy, as well as the patient’s tolerability of the drug, the presence and severity of side effects.
Overdose: Symptoms: inhibition of the function of the hypothalamic-pituitary-adrenal system (including secondary adrenal insufficiency). Treatment is symptomatic. If necessary, correct electrolyte imbalance, discontinue the drug (for long-term therapy, gradual withdrawal).
Interaction: Interactions with other drugs have not been described to date. Due to the chemical properties of mometasone furoate, it is incompatible with alkalis.
Special instructions: If there is no effect within 2 weeks of drug therapy, the diagnosis should be clarified. When applied to large areas of skin for a long time, especially when using occlusive dressings, systemic action of GCS may develop. Given this, it is necessary to monitor the function of the hypothalamic-pituitary-adrenal system. Propylene glycol, which is part of the drug, may cause irritation at the site of application. In such cases, use of the drug should be discontinued and appropriate treatment should be prescribed. It should be borne in mind that GCS can change the manifestation of some skin diseases, which can complicate the diagnosis. In addition, the use of GCS may cause a delay in wound healing. With long-term therapy with GCS, sudden cessation of therapy can lead to the development of rebound syndrome, manifested in the form of dermatitis with intense redness of the skin and a burning sensation. Therefore, after a long course of treatment, the drug should be discontinued gradually, for example, by switching to an intermittent treatment regimen before stopping it completely. Due to the fact that in children the ratio of surface area to body weight is greater than in adults, children are at greater risk of suppressing the function of the hypothalamic-pituitary-adrenal system and developing Cushing's syndrome when using any topical corticosteroids. Long-term treatment of children with GCS can lead to disruption of their growth and development. The use of the drug in children for more than 3 weeks has not been studied. Children should receive the minimum dose of the drug sufficient to achieve an effect. There is no data on the adverse effects of the drug on the ability to drive vehicles and operate machinery.
Storage conditions: In a dry place at a temperature from +2C to +30C. Keep out of the reach of children.
Dispensing order: Dispensed by prescription
